William Panenka, a 10% Holder, acquired 2,050,000 Common Shares on a direct ownership basis at a price of $0.100 through a prospectus or prospectus exempt offering on December 30th, 2020. The insider also acquired 2,050,000 Warrants on a direct ownership basis at an exercise price of $0.200 until December 30, 2021. This represents a $205,000 investment into the company's shares and an account share holdings change of 51.3%.
Yu Cai Huang, a 10% Holder, acquired 100,000 Common Shares on an indirect ownership basis for registered holder Huang Consulting Corp.
NeonMind is developing and commercializing products that contain legal
medicinal mushrooms and products that may contain psychedelic compounds.
Its first proposed drug candidate involves the administration of
psilocybin (a complex organic compound found in psychedelic mushrooms)
as a treatment for obesity and related illnesses for which NeonMind is
conducting a preclinical trial at the University of British Columbia.
No Comments